Science


Magical (Psychedelic) Thinking in the Era of Climate Change and COVID-19


Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.

DARE to Resist White Supremacy and The Police


American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

Aldous Huxley on the decline of mental health following “progress” in capitalist democracies


Aldous Huxley's thoughts on “progress” in capitalist democracies, why people take drugs, and the role of psychedelics in people's lives.

MindMed’s CEO Jamon “JR” Rahn Wants Nothing To Do With Those Psychedelic Decrim People


"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

Field Trip Announces “World’s First” Virtual Psychedelic Therapy, But Forgets To Mention They Aren’t the First and No Psychedelics Are Involved


Field Trip Ventures leads the charge to use “psychedelic” as a marketing buzzword for any kind of niche therapy.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think


Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Indie Film ‘Debbie and Doug Drop Acid in the Desert’ is a Visual and Emotional Trip


'Debbie and Doug Drop Acid in the Desert' director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.

How psychedelic clinical trials are being affected by coronavirus


Almost all clinical psychedelic drug research is being affected in some way or another by COVID-19. But, response measures vary from one organization to the next.

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism


As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer


In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers


The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS


After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency


Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics


Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Could wearable microdosing technology be a thing one day?


Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

An open letter to the newly founded Center for Psychedelic Research at Johns Hopkins


With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

MDMA Expanded Access is almost here. What’s it all about?


The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

Will MDMA-assisted psychotherapy be covered by health insurance?


Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

How will MDMA be rescheduled in the future? You may be disappointed


What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

The Future of MDMA: Phase 3 and Beyond


What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access. 

Science


Magical (Psychedelic) Thinking in the Era of Climate Change and COVID-19


Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.

DARE to Resist White Supremacy and The Police


American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

Aldous Huxley on the decline of mental health following “progress” in capitalist democracies


Aldous Huxley's thoughts on “progress” in capitalist democracies, why people take drugs, and the role of psychedelics in people's lives.

MindMed’s CEO Jamon “JR” Rahn Wants Nothing To Do With Those Psychedelic Decrim People


"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

Field Trip Announces “World’s First” Virtual Psychedelic Therapy, But Forgets To Mention They Aren’t the First and No Psychedelics Are Involved


Field Trip Ventures leads the charge to use “psychedelic” as a marketing buzzword for any kind of niche therapy.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think


Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Indie Film ‘Debbie and Doug Drop Acid in the Desert’ is a Visual and Emotional Trip


'Debbie and Doug Drop Acid in the Desert' director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.

How psychedelic clinical trials are being affected by coronavirus


Almost all clinical psychedelic drug research is being affected in some way or another by COVID-19. But, response measures vary from one organization to the next.

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism


As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer


In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers


The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS


After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency


Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics


Shlomi Raz, CEO of Eleusis Benefit Corporation, made false claims about psychedelics. We asked multiple ethnobotanists, a medical anthropologist, and a chemist if they could help us set the record straight.

Could wearable microdosing technology be a thing one day?


Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

An open letter to the newly founded Center for Psychedelic Research at Johns Hopkins


With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

MDMA Expanded Access is almost here. What’s it all about?


The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

Will MDMA-assisted psychotherapy be covered by health insurance?


Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

How will MDMA be rescheduled in the future? You may be disappointed


What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

The Future of MDMA: Phase 3 and Beyond


What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access.